Royalty Pharma (NASDAQ:RPRX) EVP Sells $508,452.12 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 9,099 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total value of $508,452.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Wednesday, June 24th, Marshall Urist sold 9,098 shares of Royalty Pharma stock. The stock was sold at an average price of $55.18, for a total value of $502,027.64.
• On Wednesday, May 20th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $52.75, for a total value of $721,831.00.
• On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04.

Royalty Pharma Price Performance

RPRX stock opened at $57.77 on Friday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a twelve month low of $34.08 and a twelve month high of $57.80. The company’s 50 day moving average is $53.56 and its two-hundred day moving average is $47.23. The stock has a market cap of $33.27 billion, a P/E ratio of 39.30, a PEG ratio of 1.59 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The business had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. Research analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a $0.235 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma’s payout ratio is 63.95%.

Analyst Ratings Changes

Several brokerages have issued reports on RPRX. Weiss Ratings lowered Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. UBS Group boosted their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Citigroup upped their target price on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley raised their price target on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Finally, JPMorgan Chase & Co. lifted their price target on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $53.71.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada raised its holdings in shares of Royalty Pharma by 367.7% in the first quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after buying an additional 160,191 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock worth $2,490,000 after buying an additional 13,489 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Royalty Pharma during the first quarter worth about $264,000. Intech Investment Management LLC increased its position in Royalty Pharma by 41.0% in the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock valued at $1,494,000 after acquiring an additional 13,951 shares during the period. Finally, Invesco Ltd. increased its position in Royalty Pharma by 21.4% in the 2nd quarter. Invesco Ltd. now owns 1,559,378 shares of the biopharmaceutical company’s stock valued at $56,184,000 after acquiring an additional 274,960 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.